SCHEMBL605656

SCHEMBL605656

Cc1ccc(C=O)c(CO)c1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SRC P12931 2/20 0.51
ALDH1A1 P00352 5/20 0.42
ERN1 O75460 2/20 0.42
KDM4E B2RXH2 2/20 0.40
GAA P10253 1/20 0.40
CYP2A6 P11509 1/20 0.37
AMY1A P0DUB6 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
USP2 O75604 1/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
AOX1 Q06278 1/20 0.36
TYR P14679 2/20 0.35
TRIM24 O15164 2/20 0.35
TRIM33 Q9UPN9 2/20 0.35
TSHR P16473 1/20 0.34
TAAR1 Q96RJ0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL606252 0.83 SRC (0.50) SRCALDH1A1ERN1KDM4EGAA
SCHEMBL16494601 0.80 SRC (0.47) SRCALDH1A1ERN1KDM4EGAA
SCHEMBL9806957 0.79 SRC (0.75) SRCALDH1A1ERN1KDM4EGAA
SCHEMBL28765524 0.78 SRC (0.50) SRCALDH1A1ERN1KDM4EGAA
SCHEMBL5527536 0.78 TYR (0.40) ERN1TYRTRIM24TRIM33
SCHEMBL28063870 0.78 EGFR (0.47) SRCERN1KDM4E
SCHEMBL13967778 0.77 SRC (0.45) SRCALDH1A1ERN1KDM4EGAA
SCHEMBL17749073 0.77 SRC (0.45) SRCALDH1A1ERN1KDM4EGAA
SCHEMBL15609817 0.77 EGFR (0.55) SRCALDH1A1LMNAHPGD
SCHEMBL15609816 0.77 EGFR (0.55) SRCALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11273168-B2 Methods of treating anxiety by administering a substituted quinolone OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2022-03-15 US disclosed
EP-1890992-B1 AN ENRICHMENT PROCESS USING COMPOUNDS USEFUL IN A POLYESTER PROCESS GRUPO PETROTEMEX SA DE CV (MX) 2019-10-23 EP disclosed
EP-1888498-B1 A PROCESS TO PRODUCE AN ENRICHMENT FEED GRUPO PETROTEMEX SA DE CV (MX) 2019-06-26 EP disclosed
EP-1888497-B1 A PROCESS TO PRODUCE AN ENRICHED COMPOSITION THROUGH THE USE OF A CATALYST REMOVAL ZONE AND AN ENRICHMENT ZONE GRUPO PETROTEMEX SA DE CV (MX) 2019-04-17 EP disclosed
EP-2066612-B1 A PROCESS TO PRODUCE AN ENRICHMENT FEED GRUPO PETROTEMEX SA DE CV (MX) 2018-08-01 EP disclosed
US-10029973-B2 Optimized liquid-phase oxidation GROPO PETROTEMEX, S.A. DE C.V. (MX) 2018-07-24 US disclosed
US-20180072648-A1 OPTIMIZED LIQUID-PHASE OXIDATION GRUPO PETROTEMEX, S.A. DE C.V. (MX) 2018-03-15 US disclosed
EP-2316566-B1 Bubble column reactor for gas-liquid exchange reactions GRUPO PETROTEMEX SA DE CV (MX) 2017-11-22 EP disclosed
EP-1791800-B1 OPTIMIZED LIQUID-PHASE OXIDATION GRUPO PETROTEMEX SA DE CV (MX) 2017-11-01 EP disclosed
EP-1881953-B1 A PROCESS TO PRODUCE AN ENRICHED CARBOXYLIC ACID COMPOSITION GRUPO PETROTEMEX SA DE CV (MX) 2017-10-25 EP disclosed
US-20060047151-A1 Optimized liquid-phase oxidation ALPEK POLYESTER, S.A. DE C.V. (MX) 2006-03-02 US disclosed
US-20060047155-A1 Optimized liquid-phase oxidation ALPEK POLYESTER, S.A. DE C.V. (MX) 2006-03-02 US disclosed
US-20060047149-A1 Optimized liquid-phase oxidation GRUPO PETROTEMEX, S.A. DE C.V. (MX) 2006-03-02 US disclosed
US-20060047157-A1 Optimized liquid-phase oxidation ALPEK POLYESTER, S.A. DE C.V. (MX) 2006-03-02 US disclosed
US-20060047154-A1 Optimized liquid-phase oxidation GRUPO PETROTEMEX, S.A. DE C.V. (MX) 2006-03-02 US disclosed
US-20060047142-A1 Optimized liquid-phase oxidation GRUPO PETROTEMEX, S.A. DE C.V. (MX) 2006-03-02 US disclosed
US-20060047161-A1 Optimized liquid-phase oxidation ALPEK POLYESTER, S.A. DE C.V. (MX) 2006-03-02 US disclosed
US-20060047143-A1 Optimized liquid-phase oxidation ALPEK POLYESTER, S.A. DE C.V. (MX) 2006-03-02 US disclosed
US-20060047163-A1 Optimized liquid-phase oxidation ALPEK POLYESTER, S.A. DE C.V. (MX) 2006-03-02 US disclosed
US-20060047147-A1 Carried out in a bubble column reactor that provides for a highly efficient reaction at relatively low temperatures; oxidizing p-xylene to form terephthalic acid that can be purified more easily that if higher temperatures were required. ALPEK POLYESTER, S.A. DE C.V. (MX) 2006-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11273168-B2 Methods of treating anxiety by administering a substituted quinolone CRH, MC2R, HTR3C SRC 3281/4885ALDH1A1 1739/4885ERN1 3640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.